舌下神经刺激器治疗13岁以下唐氏综合症儿童阻塞性睡眠呼吸暂停

IF 1.3 4区 医学 Q3 OTORHINOLARYNGOLOGY
Minjee Kim , Lucy J. Xu , E'Ching Shih , Kevin S. Gipson , Brian G. Skotko , Patrick Scheffler , Christopher J. Hartnick
{"title":"舌下神经刺激器治疗13岁以下唐氏综合症儿童阻塞性睡眠呼吸暂停","authors":"Minjee Kim ,&nbsp;Lucy J. Xu ,&nbsp;E'Ching Shih ,&nbsp;Kevin S. Gipson ,&nbsp;Brian G. Skotko ,&nbsp;Patrick Scheffler ,&nbsp;Christopher J. Hartnick","doi":"10.1016/j.ijporl.2025.112497","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Obstructive Sleep Apnea (OSA) is prevalent among children with Down syndrome (DS). While adenotonsillectomy is the first-line treatment for these patients, many do not achieve resolution of OSA. The U.S. Food and Drug Administration has approved HGNS implantation for children with DS, ages 13 and above. However, there remains a need for HGNS implantation in children under 13 with severe OSA. The objective of this study was to determine the safety and efficacy of HGNS placement in children &lt;13 years of age with DS and severe OSA.</div></div><div><h3>Study design</h3><div>Retrospective cohort study.</div></div><div><h3>Setting</h3><div>Two academic institutions.</div></div><div><h3>Methods</h3><div>This study included children &lt;13 years of age with DS and severe OSA who had HGNS implantation. Patient characteristics, postoperative complications, and response to therapy were recorded.</div></div><div><h3>Results</h3><div>A total of 29 children were included. The median age of the patients was 10 years old (range 4–12 years), with 19 patients (65.5 %) male. All 29 children were safely implanted with no serious adverse events. There was one mild wound dehiscence (Adverse Event), which resolved with antibiotic ointment and pressure dressing, and no adverse device effects. The median pre-op OAHI was 18.4 (IQR 13.2–22.3), and the median post-op OAHI was 3.9 (IQR 2.3–5.5) (<em>p</em> &lt; 0.001). At 6 months post-op, 20 patients (95.2 %) had OAHI reduction of 50 % or more.</div></div><div><h3>Conclusion</h3><div>HGNS implantation in children with DS and severe OSA can be safely performed in children ages 4–13, and initial efficacy studies demonstrate outcomes similar to children over 13.</div></div>","PeriodicalId":14388,"journal":{"name":"International journal of pediatric otorhinolaryngology","volume":"196 ","pages":"Article 112497"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hypoglossal nerve stimulator for obstructive sleep apnea in children with down syndrome younger than 13\",\"authors\":\"Minjee Kim ,&nbsp;Lucy J. Xu ,&nbsp;E'Ching Shih ,&nbsp;Kevin S. Gipson ,&nbsp;Brian G. Skotko ,&nbsp;Patrick Scheffler ,&nbsp;Christopher J. Hartnick\",\"doi\":\"10.1016/j.ijporl.2025.112497\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Obstructive Sleep Apnea (OSA) is prevalent among children with Down syndrome (DS). While adenotonsillectomy is the first-line treatment for these patients, many do not achieve resolution of OSA. The U.S. Food and Drug Administration has approved HGNS implantation for children with DS, ages 13 and above. However, there remains a need for HGNS implantation in children under 13 with severe OSA. The objective of this study was to determine the safety and efficacy of HGNS placement in children &lt;13 years of age with DS and severe OSA.</div></div><div><h3>Study design</h3><div>Retrospective cohort study.</div></div><div><h3>Setting</h3><div>Two academic institutions.</div></div><div><h3>Methods</h3><div>This study included children &lt;13 years of age with DS and severe OSA who had HGNS implantation. Patient characteristics, postoperative complications, and response to therapy were recorded.</div></div><div><h3>Results</h3><div>A total of 29 children were included. The median age of the patients was 10 years old (range 4–12 years), with 19 patients (65.5 %) male. All 29 children were safely implanted with no serious adverse events. There was one mild wound dehiscence (Adverse Event), which resolved with antibiotic ointment and pressure dressing, and no adverse device effects. The median pre-op OAHI was 18.4 (IQR 13.2–22.3), and the median post-op OAHI was 3.9 (IQR 2.3–5.5) (<em>p</em> &lt; 0.001). At 6 months post-op, 20 patients (95.2 %) had OAHI reduction of 50 % or more.</div></div><div><h3>Conclusion</h3><div>HGNS implantation in children with DS and severe OSA can be safely performed in children ages 4–13, and initial efficacy studies demonstrate outcomes similar to children over 13.</div></div>\",\"PeriodicalId\":14388,\"journal\":{\"name\":\"International journal of pediatric otorhinolaryngology\",\"volume\":\"196 \",\"pages\":\"Article 112497\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of pediatric otorhinolaryngology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0165587625002848\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of pediatric otorhinolaryngology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165587625002848","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:阻塞性睡眠呼吸暂停(OSA)在唐氏综合征(DS)患儿中普遍存在。虽然腺扁桃体切除术是这些患者的一线治疗方法,但许多患者并没有实现OSA的缓解。美国食品和药物管理局(fda)已批准为13岁及以上的DS儿童植入HGNS。然而,13岁以下患有严重OSA的儿童仍然需要植入HGNS。本研究的目的是确定HGNS在13岁儿童退行性椎体滑移合并严重OSA患者中的安全性和有效性。研究设计回顾性队列研究。两个学术机构。方法本研究纳入13岁的DS合并重度OSA患儿,并植入HGNS。记录患者特征、术后并发症及对治疗的反应。结果共纳入29例患儿。患者中位年龄为10岁(范围4-12岁),男性19例(65.5%)。29例患儿均安全植入,无严重不良事件发生。有1例轻度创面裂开(不良事件),经抗生素软膏和压力敷料解决,无不良器械反应。术前OAHI中位数为18.4 (IQR为13.2-22.3),术后OAHI中位数为3.9 (IQR为2.3-5.5)(p <;0.001)。术后6个月,20例患者(95.2%)OAHI降低50%或以上。结论hgns植入术在4-13岁的DS合并严重OSA患儿中是安全的,初步疗效研究显示与13岁以上患儿相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Hypoglossal nerve stimulator for obstructive sleep apnea in children with down syndrome younger than 13

Objective

Obstructive Sleep Apnea (OSA) is prevalent among children with Down syndrome (DS). While adenotonsillectomy is the first-line treatment for these patients, many do not achieve resolution of OSA. The U.S. Food and Drug Administration has approved HGNS implantation for children with DS, ages 13 and above. However, there remains a need for HGNS implantation in children under 13 with severe OSA. The objective of this study was to determine the safety and efficacy of HGNS placement in children <13 years of age with DS and severe OSA.

Study design

Retrospective cohort study.

Setting

Two academic institutions.

Methods

This study included children <13 years of age with DS and severe OSA who had HGNS implantation. Patient characteristics, postoperative complications, and response to therapy were recorded.

Results

A total of 29 children were included. The median age of the patients was 10 years old (range 4–12 years), with 19 patients (65.5 %) male. All 29 children were safely implanted with no serious adverse events. There was one mild wound dehiscence (Adverse Event), which resolved with antibiotic ointment and pressure dressing, and no adverse device effects. The median pre-op OAHI was 18.4 (IQR 13.2–22.3), and the median post-op OAHI was 3.9 (IQR 2.3–5.5) (p < 0.001). At 6 months post-op, 20 patients (95.2 %) had OAHI reduction of 50 % or more.

Conclusion

HGNS implantation in children with DS and severe OSA can be safely performed in children ages 4–13, and initial efficacy studies demonstrate outcomes similar to children over 13.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.20
自引率
6.70%
发文量
276
审稿时长
62 days
期刊介绍: The purpose of the International Journal of Pediatric Otorhinolaryngology is to concentrate and disseminate information concerning prevention, cure and care of otorhinolaryngological disorders in infants and children due to developmental, degenerative, infectious, neoplastic, traumatic, social, psychiatric and economic causes. The Journal provides a medium for clinical and basic contributions in all of the areas of pediatric otorhinolaryngology. This includes medical and surgical otology, bronchoesophagology, laryngology, rhinology, diseases of the head and neck, and disorders of communication, including voice, speech and language disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信